Annual Cash & Cash Equivalents
$8.71 M
-$8.19 M-48.45%
December 31, 2024
Summary
- As of February 24, 2025, APVO annual cash & cash equivalents is $8.71 million, with the most recent change of -$8.19 million (-48.45%) on December 31, 2024.
- During the last 3 years, APVO annual cash & cash equivalents has fallen by -$36.33 million (-80.65%).
- APVO annual cash & cash equivalents is now -80.65% below its all-time high of $45.04 million, reached on December 31, 2021.
Performance
APVO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$8.71 M
+$961.00 K+12.40%
December 31, 2024
Summary
- As of February 24, 2025, APVO quarterly cash and cash equivalents is $8.71 million, with the most recent change of +$961.00 thousand (+12.40%) on December 31, 2024.
- Over the past year, APVO quarterly cash and cash equivalents has stayed the same.
- APVO quarterly cash and cash equivalents is now -88.51% below its all-time high of $75.83 million, reached on September 30, 2017.
Performance
APVO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
APVO Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -48.5% | 0.0% |
| 3 y3 years | -80.7% | 0.0% |
| 5 y5 years | -30.0% | 0.0% |
APVO Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -80.7% | at low | -80.7% | +12.4% |
| 5 y | 5-year | -80.7% | at low | -85.6% | +14.7% |
| alltime | all time | -80.7% | +142.5% | -88.5% | +87.9% |
Aptevo Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $8.71 M(-48.5%) | $8.71 M(+12.4%) |
| Sep 2024 | - | $7.75 M(-3.9%) |
| Jun 2024 | - | $8.07 M(-21.3%) |
| Mar 2024 | - | $10.25 M(-39.4%) |
| Dec 2023 | $16.90 M(-25.3%) | $16.90 M(-11.5%) |
| Sep 2023 | - | $19.11 M(-9.0%) |
| Jun 2023 | - | $21.01 M(-17.1%) |
| Mar 2023 | - | $25.33 M(+11.9%) |
| Dec 2022 | $22.64 M(-49.7%) | $22.64 M(+2.2%) |
| Sep 2022 | - | $22.15 M(-24.7%) |
| Jun 2022 | - | $29.43 M(-15.9%) |
| Mar 2022 | - | $34.99 M(-22.3%) |
| Dec 2021 | $45.04 M(+12.7%) | $45.04 M(-13.6%) |
| Sep 2021 | - | $52.12 M(-13.7%) |
| Jun 2021 | - | $60.39 M(+5.0%) |
| Mar 2021 | - | $57.52 M(+43.9%) |
| Dec 2020 | $39.98 M | $39.98 M(+60.3%) |
| Sep 2020 | - | $24.94 M(+228.2%) |
| Jun 2020 | - | $7.60 M(-38.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $12.26 M(-1.5%) |
| Dec 2019 | $12.45 M(-59.4%) | $12.45 M(-29.6%) |
| Sep 2019 | - | $17.68 M(-15.6%) |
| Jun 2019 | - | $20.96 M(-43.4%) |
| Mar 2019 | - | $37.01 M(+20.8%) |
| Dec 2018 | $30.64 M(+331.8%) | $30.64 M(+7.7%) |
| Sep 2018 | - | $28.45 M(+293.6%) |
| Jun 2018 | - | $7.23 M(-38.9%) |
| Mar 2018 | - | $11.83 M(+66.7%) |
| Dec 2017 | $7.09 M(-26.7%) | $7.09 M(-90.6%) |
| Sep 2017 | - | $75.83 M(+240.5%) |
| Jun 2017 | - | $22.27 M(+58.9%) |
| Mar 2017 | - | $14.01 M(+44.8%) |
| Dec 2016 | $9.68 M(+108.7%) | $9.68 M(-11.2%) |
| Sep 2016 | - | $10.89 M(+98.2%) |
| Jun 2016 | - | $5.50 M(-87.8%) |
| Mar 2016 | - | $45.00 M(+870.5%) |
| Dec 2015 | $4.64 M(+29.1%) | $4.64 M |
| Dec 2014 | $3.59 M | - |
FAQ
- What is Aptevo Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Aptevo Therapeutics?
- What is Aptevo Therapeutics annual cash & cash equivalents year-on-year change?
- What is Aptevo Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Aptevo Therapeutics?
- What is Aptevo Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Aptevo Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of APVO is $8.71 M
What is the all time high annual cash & cash equivalents for Aptevo Therapeutics?
Aptevo Therapeutics all-time high annual cash & cash equivalents is $45.04 M
What is Aptevo Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, APVO annual cash & cash equivalents has changed by -$8.19 M (-48.45%)
What is Aptevo Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of APVO is $8.71 M
What is the all time high quarterly cash and cash equivalents for Aptevo Therapeutics?
Aptevo Therapeutics all-time high quarterly cash and cash equivalents is $75.83 M
What is Aptevo Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, APVO quarterly cash and cash equivalents has changed by $0.00 (0.00%)